Creative Biolabs recently integrated its biosimilar segment, launching a comprehensive solution for high-precision characterization and customized pipeline development.
SHIRLEY, NY, January 23, 2026 /24-7PressRelease/ — When producing biosimilar medicines, pharmaceutical firms must demonstrate that their products are “highly similar” or statistically equivalent to the reference drug. Following the strategic upgrade of its biosimilar development services, Creative Biolabs is strengthening its capabilities in physicochemical characterization and biological activity comparison.
A chief researcher at Creative Biolabs said, “At this time, our platform offers an extensive array of physicochemical evaluations, which include primary sequence validation, high-order structure (HOS) analysis, and charge variant analysis. For biological activity, we have established a series of cell-based functional experiments to ensure high consistency with the original drug in terms of binding affinity and downstream signal transduction.”
Targeted pipeline: Development experience covering 20+ popular varieties
Creative Biolabs is highlighting its advancements in developing biosimilar pipelines, which cater to the largest and fastest-growing sector of the monoclonal antibodies market. Currently, the company’s development catalogue has covered analogues of globally best-selling drugs such as Rituximab, Trastuzumab, and Adalimumab.
“We not only offer off-the-shelf solutions, but we try to solve discrete technical challenges,” stated the researcher. “For example, for the analogue of Bevacizumab, we use proprietary high-expression cell line construction technology to significantly increase production and optimize downstream purification processes to remove trace impurities.”
One-stop CDMO: From molecular design to 2000 L large-scale production
To break down the barriers between research and commercialization, Creative Biolabs, through its one-stop CDMO solution, provides highly flexible production support. This platform not only supports monoclonal antibodies but also extends to bispecific antibodies, ADC drugs, and viral vectors.
The CDMO platform of Creative Biolabs includes the following important considerations:
Cell line development: Using platforms like CHO and HEK293 and offering high-yield stable clone screening
Upstream process (USP): Supporting bioreactor scales of 50L, 200L, 500L to 2000L
Downstream process (DSP): Involving advanced protein A affinity chromatography, ion exchange, and virus filtration processes
Quality control: Environmental monitoring in accordance with GMP standards and a multi-dimensional quality detection system
“Many partners performed well in the pilot stage but encountered yield reduction during scale-up,” continued the researcher. “Our platform addresses this specifically. With our linear scale-up technology and single-use bioreactor systems, we ensure process consistency from initial cloning to commercial GMP production, effectively reducing regulatory risk.”
About
Creative Biolabs is an international leading service provider specializing in the field of biotechnology. Its business covers antibody discovery, custom services, drug development, and CDMO production. The company provides comprehensive research support to global pharmaceutical giants and biotechnology startups.
—
For the original version of this press release, please visit 24-7PressRelease.com here
Legal Disclaimer:
The content on this page is syndicated from independent third-party providers. Kyrion Media makes no warranties or representations regarding the accuracy, completeness, legality, or reliability of the information, including text, images, videos, or licenses. If you are affiliated with this content or have any complaints, copyright concerns, or requests for removal, please contact us at retract@kyrionmedia.com with the specific URL of the content in question. We will review and address valid requests promptly.
